Developer docs
API playgroundTry for free, no card

Search company profiles

Bioinduction

Full company profile

uuid00068kv

Namestring
Bioinduction
Legal namestring
Bioinduction Ltd.
Company typeenum
Private
Founded yearint
2002
Descriptiontext

Bioinduction is a UK-based med-tech company founded in 2005 that specializes in neuromodulation technology, principally developing deep brain stimulation (DBS) implantable pulse generators under the Picostim brand. The Picostim system comprises an implantable pulse generator (IPG), a patient controller with rechargeable hardware, and clinician-programmable stimulation parameters, targeting movement and neurological disorders including Parkinson's disease, essential tremor, dystonia, and epilepsy. The company subsequently extended into urology with the Amber-UI, a wearable neurostimulation device aimed at mixed urinary incontinence, broadening its therapeutic footprint across two distinct neurostimulation indications.

The Picostim platform is presented through Amber Therapeutics' DBS patient information portal, which publishes instructional videos on linking the patient controller, starting and adjusting stimulation, recharging, and changing programs, indicating the system is in clinical deployment with clinician-supported patients. A second-generation patient controller, with revised indicator lighting, menu symbols, and recessed cable connectors, is in active production relative to the original device, showing continued hardware iteration of the IPG ecosystem.

In September 2023, Bioinduction was acquired by Amber Therapeutics Ltd. and ceased operating as an independent entity. Funding history consists only of two small UK innovation grants totaling approximately $27,000 from SBRI Healthcare and Innovate UK in 2017 and 2018, with no disclosed equity rounds or commercial revenue prior to acquisition. Following the transaction, Bioinduction's Picostim and Amber-UI technologies are commercialized under Amber Therapeutics' infrastructure; detailed pricing, distribution channels, and segment-level revenue mechanics are not publicly disclosed.

Short descriptiontext

Bioinduction is a UK-based neuromodulation company that developed the Picostim implantable deep brain stimulation system for Parkinson's disease, essential tremor, dystonia, and epilepsy, and the Amber-UI wearable device for mixed urinary incontinence. It was acquired by Amber Therapeutics in September 2023.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBristol, United Kingdom
HQ citystring
Bristol
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
deep brain stimulation devices, implantable pulse generators, wearable neurostimulation devices, neuromodulation therapy hardware, neurostimulation medical devices
Industry1 code
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Neurostimulation Medical Devices
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Supply Chain, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Bioinduction developed and manufactured neuromodulation medical devices, including the Picostim Implantable Pulse Generator (IPG) deep brain stimulation system for treating neurological conditions such as Parkinson's disease, essential tremor, dystonia, and epilepsy, and the Amber-UI wearable neurostimulation device targeting mixed urinary incontinence. Its core business was hardware design and delivery of neurostimulation systems intended for clinical use by neurosurgery teams and healthcare providers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Bioinduction was a UK-based med-tech company specializing in neurostimulation technology. Prior to its acquisition by Amber Therapeutics in September 2023, Bioinduction developed the Amber-UI wearable neurostimulation device aimed at treating conditions such as mixed urinary incontinence. The acquisition enabled Amber Therapeutics to strengthen its hardware capabilities and accelerate commercialization of neurostimulation therapies. The company's technology has been integrated into Amber Therapeutics' neuromodulation platform following the acquisition.

Product and service2 records
1Picostim IPG (Implantable Pulse Generator)
CategoryImplantable neurostimulation devices
Description

Deep brain stimulation implantable pulse generator system designed for patients with neurological conditions such as Parkinson's disease, essential tremor, dystonia, and epilepsy. The system is used by neurosurgery teams and DBS clinicians who implant and program the device, and includes a patient controller for starting, stopping, adjusting stimulation, recharging, changing programs, and linking to the IPG.

2Amber-UI Wearable Neurostimulation Device
CategoryWearable neurostimulation devices
Description

A wearable neurostimulation device developed by Bioinduction targeting neuromodulation therapy for patients with mixed urinary incontinence. The device is part of Amber Therapeutics' neuromodulation platform and is being advanced toward commercialization using hardware capabilities acquired from Bioinduction.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global leader in deep brain stimulation with the Activa PC and Activa RC systems, directly competing with Bioinduction's Picostim DBS platform across Parkinson's, essential tremor, dystonia, and epilepsy indications.

2Abbott
TypeDirect peer
Description

Markets the Infinity DBS system following its St. Jude Medical acquisition; competes head-to-head with Picostim in implantable neurostimulation for movement disorders.

TypeDirect peer
Description

Offers the Vercise DBS system and is a direct DBS competitor; also active in spinal cord and deep brain stimulation, overlapping with Bioinduction's core implantable neurostimulation space.

TypeDirect peer
Description

Specializes in sacral and tibial neuromodulation for urinary and bowel dysfunction; a direct analogue to the Amber-UI wearable for mixed urinary incontinence, validating the commercial model Bioinduction's device is pursuing.

TypeBroad incumbent
Description

Spinal cord stimulation (Senza) leader; operates in the same implantable neuromodulation category as Picostim but addresses chronic pain rather than movement disorders, making it a broader neuromodulation incumbent.

TypeDirect peer
Description

Implantable neurostimulator (hypoglossal nerve stimulation) treating obstructive sleep apnea; comparable to Bioinduction as an implantable neurostimulation company targeting chronic conditions via electrical stimulation.

TypeEmerging player
Description

Closed-loop spinal cord stimulation developer with the Evoke system; an emerging player in implantable neurostimulation, partially overlapping with Bioinduction's broader neuromodulation platform.

8MicroPort Scientific
TypeRegional player
Description

China-based manufacturer with a DBS product line; regional player in the Asian market that competes with Bioinduction's DBS technology in Asia-Pacific geographies.

9PINS Medical
TypeRegional player
Description

Beijing PINS Medical produces DBS systems primarily for the Chinese market; comparable hardware competitor focused on a different geography than Bioinduction/Amber.

10SceneRay
TypeEmerging player
Description

China-based emerging DBS device company developing next-generation deep brain stimulation systems; partial overlap with Bioinduction's Picostim in the broader DBS category.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bioinduction

Neurostimulation Medical Devicesbioinduction.com

Bioinduction is a UK-based neuromodulation company that developed the Picostim implantable deep brain stimulation system for Parkinson's disease, essential tremor, dystonia, and epilepsy, and the Amber-UI wearable device for mixed urinary incontinence. It was acquired by Amber Therapeutics in September 2023.

What Bioinduction does

Bioinduction is a UK-based med-tech company founded in 2005 that specializes in neuromodulation technology, principally developing deep brain stimulation (DBS) implantable pulse generators under the Picostim brand. The Picostim system comprises an implantable pulse generator (IPG), a patient controller with rechargeable hardware, and clinician-programmable stimulation parameters, targeting movement and neurological disorders including Parkinson's disease, essential tremor, dystonia, and epilepsy. The company subsequently extended into urology with the Amber-UI, a wearable neurostimulation device aimed at mixed urinary incontinence, broadening its therapeutic footprint across two distinct neurostimulation indications.

The Picostim platform is presented through Amber Therapeutics' DBS patient information portal, which publishes instructional videos on linking the patient controller, starting and adjusting stimulation, recharging, and changing programs, indicating the system is in clinical deployment with clinician-supported patients. A second-generation patient controller, with revised indicator lighting, menu symbols, and recessed cable connectors, is in active production relative to the original device, showing continued hardware iteration of the IPG ecosystem.

In September 2023, Bioinduction was acquired by Amber Therapeutics Ltd. and ceased operating as an independent entity. Funding history consists only of two small UK innovation grants totaling approximately $27,000 from SBRI Healthcare and Innovate UK in 2017 and 2018, with no disclosed equity rounds or commercial revenue prior to acquisition. Following the transaction, Bioinduction's Picostim and Amber-UI technologies are commercialized under Amber Therapeutics' infrastructure; detailed pricing, distribution channels, and segment-level revenue mechanics are not publicly disclosed.

Bioinduction firmographics

Firmographics
Name
Bioinduction
Legal name
Bioinduction Ltd.
Website
https://bioinduction.com
Company type
Private
Founded year
2002
Operating status
Acquired
Headcount range
1–10 employees
Short description
Bioinduction is a UK-based neuromodulation company that developed the Picostim implantable deep brain stimulation system for Parkinson's disease, essential tremor, dystonia, and epilepsy, and the Amber-UI wearable device for mixed urinary incontinence. It was acquired by Amber Therapeutics in September 2023.
Ownership category
akta.pro rank

Bioinduction industry classification

Industry
Product category
Neurostimulation Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Deep brain stimulation devices
  • Implantable pulse generators
  • Wearable neurostimulation devices
  • Neuromodulation therapy hardware
  • Neurostimulation medical devices

Where Bioinduction is headquartered

Location

Headquarters

HQ city
Bristol
HQ country
United Kingdom
HQ region
Europe

Markets served

Bioinduction business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations

Bioinduction product offering

Product offering

Core offering

Bioinduction developed and manufactured neuromodulation medical devices, including the Picostim Implantable Pulse Generator (IPG) deep brain stimulation system for treating neurological conditions such as Parkinson's disease, essential tremor, dystonia, and epilepsy, and the Amber-UI wearable neurostimulation device targeting mixed urinary incontinence. Its core business was hardware design and delivery of neurostimulation systems intended for clinical use by neurosurgery teams and healthcare providers.

Product overview

Bioinduction was a UK-based med-tech company specializing in neurostimulation technology. Prior to its acquisition by Amber Therapeutics in September 2023, Bioinduction developed the Amber-UI wearable neurostimulation device aimed at treating conditions such as mixed urinary incontinence. The acquisition enabled Amber Therapeutics to strengthen its hardware capabilities and accelerate commercialization of neurostimulation therapies. The company's technology has been integrated into Amber Therapeutics' neuromodulation platform following the acquisition.

Differentiator

Problem solved

Functional benefit

Products and services

  • Picostim IPG (Implantable Pulse Generator) Deep brain stimulation implantable pulse generator system designed for patients with neurological conditions such as Parkinson's disease, essential tremor, dystonia, and epilepsy. The system is used by neurosurgery teams and DBS clinicians who implant and program the device, and includes a patient controller for starting, stopping, adjusting stimulation, recharging, changing programs, and linking to the IPG.
  • Amber-UI Wearable Neurostimulation Device A wearable neurostimulation device developed by Bioinduction targeting neuromodulation therapy for patients with mixed urinary incontinence. The device is part of Amber Therapeutics' neuromodulation platform and is being advanced toward commercialization using hardware capabilities acquired from Bioinduction.

Companies that use Bioinduction

Customer profile

Segments2 records

Ideal customer profiles2 records

Bioinduction technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Bioinduction partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves5 records

Expansion highlights4 records

Bioinduction competitors and assessment

Company assessment

Direct peers

  • Medtronic: Global leader in deep brain stimulation with the Activa PC and Activa RC systems, directly competing with Bioinduction's Picostim DBS platform across Parkinson's, essential tremor, dystonia, and epilepsy indications.
  • Abbott: Markets the Infinity DBS system following its St. Jude Medical acquisition; competes head-to-head with Picostim in implantable neurostimulation for movement disorders.
  • Boston Scientific: Offers the Vercise DBS system and is a direct DBS competitor; also active in spinal cord and deep brain stimulation, overlapping with Bioinduction's core implantable neurostimulation space.
  • Axonics: Specializes in sacral and tibial neuromodulation for urinary and bowel dysfunction; a direct analogue to the Amber-UI wearable for mixed urinary incontinence, validating the commercial model Bioinduction's device is pursuing.
  • Inspire Medical Systems: Implantable neurostimulator (hypoglossal nerve stimulation) treating obstructive sleep apnea; comparable to Bioinduction as an implantable neurostimulation company targeting chronic conditions via electrical stimulation.

Broad incumbents

  • Nevro: Spinal cord stimulation (Senza) leader; operates in the same implantable neuromodulation category as Picostim but addresses chronic pain rather than movement disorders, making it a broader neuromodulation incumbent.

Emerging players

  • Saluda Medical: Closed-loop spinal cord stimulation developer with the Evoke system; an emerging player in implantable neurostimulation, partially overlapping with Bioinduction's broader neuromodulation platform.
  • SceneRay: China-based emerging DBS device company developing next-generation deep brain stimulation systems; partial overlap with Bioinduction's Picostim in the broader DBS category.

Regional players

  • MicroPort Scientific: China-based manufacturer with a DBS product line; regional player in the Asian market that competes with Bioinduction's DBS technology in Asia-Pacific geographies.
  • PINS Medical: Beijing PINS Medical produces DBS systems primarily for the Chinese market; comparable hardware competitor focused on a different geography than Bioinduction/Amber.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Bioinduction social profiles

Digital presence

Bioinduction financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bioinduction leadership team

Management profile

Number of profiles

Profiles2 records

Bioinduction funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bioinduction M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioinduction

What does Bioinduction do?

Bioinduction developed and manufactured neuromodulation medical devices, including the Picostim Implantable Pulse Generator (IPG) deep brain stimulation system for treating neurological conditions such as Parkinson's disease, essential tremor, dystonia, and epilepsy, and the Amber-UI wearable neurostimulation device targeting mixed urinary incontinence. Its core business was hardware design and delivery of neurostimulation systems intended for clinical use by neurosurgery teams and healthcare providers.

Is Bioinduction a public or private company?

Bioinduction is a private company. It is classified as corporate owned and is currently acquired.

When was Bioinduction founded?

Bioinduction was founded in 2002. It employs 1 to 10 people.

Where is Bioinduction based?

Bioinduction is headquartered in Bristol, United Kingdom, in the Europe region.

Who are Bioinduction's main competitors?

Direct peers on record are Medtronic, Abbott, Boston Scientific, Axonics and Inspire Medical Systems. Nevro is listed as a broad incumbent. Emerging players are Saluda Medical and SceneRay. Regional players are MicroPort Scientific and PINS Medical.

Does Bioinduction have an API?

No public API is recorded for Bioinduction.

What industry is Bioinduction in?

Bioinduction's product category is Neurostimulation Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical BuyerBrain pacemaker market to hit USD 3.4BThe brain pacemaker market is projected to reach $3.4 billion by 2030, growing at a compound annual growth rate of 13.2%, driven by rising demand for dual-channel programmable pacemakers, broader clinical adoption, and technological advancements in neuromodulation devices. In September 2023, UK-based Amber Therapeutics acquired Bioinduction Limited along with its Picostim DyNeuMo neuromodulation therapy platform, positioning Amber as an integrated developer and manufacturer of intelligent closed-loop neuromodulation treatments. Medtronic introduced the Percept RC deep brain stimulation system in January 2024, featuring BrainSense technology that enables continuous brain signal monitoring for personalized patient therapy.openPR.comKey Factors and Emerging Trends Shaping the Implantable Neurostimulators Market LandscapeThe implantable neurostimulators market is projected to grow from $5.34 billion in 2021 to $11.44 billion by 2030, representing a compound annual growth rate of 11.0%, driven by technological advancements, an aging population, and expanded clinical evidence supporting neuromodulation therapies. In September 2023, UK-based med-tech company Amber Therapeutics Ltd. acquired Bioinduction Ltd. to strengthen its capabilities in developing neuromodulation therapies for mixed urinary incontinence. In December 2024, Medtronic launched its FDA-approved Percept RC neurostimulator in India, targeting neurological conditions such as Parkinson's disease, essential tremor, dystonia, and epilepsy.openPR.comAn Overview of Segmentation, Market Dynamics, and Competitive Landscape in the Electrical Stimulation Devices MarketThe electrical stimulation devices market is projected to reach $13.22 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.3%, driven by personalized neuromodulation therapies, smart implantable devices, and remote monitoring technologies. A notable acquisition occurred in September 2023 when UK-based Amber Therapeutics Ltd. acquired Bioinduction Limited, securing full control over Picostim-based hardware development and accelerating its Amber-UI neuromodulation therapy. In May 2024, US-based Soterix Medical Inc. introduced the MxN-GO EEG system, an integrated wireless platform combining high-definition transcranial electrical stimulation with EEG monitoring.openPR.comTop Players and Market Competition in the Brain Pacemaker IndustryThe global brain pacemaker market is projected to reach $3.4 billion by 2030, growing at a compound annual growth rate of 13.2%, driven by technological advances, rising demand for dual-channel programmable pacemakers, and expanded clinical applications for conditions such as Parkinson's disease and obsessive-compulsive disorder. In September 2023, UK-based Amber Therapeutics acquired Bioinduction Limited along with its Picostim DyNeuMo neuromodulation therapy platform, transforming Amber Therapeutics into a fully integrated developer and manufacturer of intelligent closed-loop neuromodulation therapies. In January 2024, Medtronic launched the Percept RC deep brain stimulation system, currently the smallest and thinnest dual-channel neurostimulator available, incorporating the company's BrainSense technology for continuous brain signal monitoring.openPR.comClosed-Loop Neuromodulation Processor Market Overview, Key Trends, and Major Player AnalysisThe closed-loop neuromodulation processor market is projected to grow from its current size to $4.63 billion by 2030, representing a compound annual growth rate of 12.9%, driven by AI-powered adaptive processors, wearable controllers, telemedicine integration, and home-based therapies. In February 2025, Medtronic received FDA approval for its BrainSense Adaptive Deep Brain Stimulation system and BrainSense Electrode Identifier, marking one of the largest commercial deployments of brain-computer interface technology for treating Parkinson's disease. Additionally, UK-based Amber Therapeutics acquired Bioinduction Limited in September 2023 to incorporate its Picostim DyNeuMo ultra-miniaturized cranial neurostimulator into its portfolio.Research and MarketsClosed-Loop Neuromodulation Processor Market Report 2025The Business Research Company released a market report forecasting the closed-loop neuromodulation processor market to grow from $2.22 billion in 2024 to $4.11 billion by 2029, driven by rising neurological disorder prevalence and technological advancements like AI integration. The report highlights key industry developments, including Medtronic's FDA approval for adaptive deep brain stimulation technology and Amber Therapeutics' acquisition of Bioinduction Limited to expand its neuromodulation capabilities.Research and MarketsClosed-Loop Neuromodulation Processor Market Report 2025The Business Research Company published a market report projecting the global closed-loop neuromodulation processor market will grow from $2.22 billion in 2024 to $4.11 billion by 2029, driven by rising neurological disorder prevalence and technological advancements like AI integration. The report highlights strategic activities by key industry players, including Medtronic's FDA approval for adaptive deep brain stimulation and Amber Therapeutics' acquisition of Bioinduction Limited to expand its neurostimulation capabilities.Research and MarketsClosed-Loop Neuromodulation Processor Market Report 2025The Business Research Company published a market report projecting the global closed-loop neuromodulation processor market to grow from $2.22 billion in 2024 to $4.11 billion by 2029, driven by rising neurological disorder prevalence and technological advancements like AI integration. Key industry developments include Medtronic's FDA approval for its BrainSense adaptive deep brain stimulation system and Amber Therapeutics' acquisition of Bioinduction Limited to expand its neurostimulation capabilities. The report also highlights significant challenges posed by U.S. tariffs and trade tensions affecting medical equipment supply chains.GlobeNewswireAmber Tx acquires Bioinduction Limited and its Picostim DyNeuMo platform, on which Amber’s closed-loop neuromodulation therapy for mixed urinary incontinence is being developedAmber Therapeutics acquired Bioinduction Limited and its Picostim DyNeuMo neuromodulation platform, which it will use for a closed-loop therapy for mixed urinary incontinence. The therapy is in a first-in-human study (AURA-2) with early safety and feasibility data, and the acquisition supports a pivotal US trial and global commercialization.GlobeNewswireAmber Tx acquires Bioinduction Limited and its Picostim DyNeuMo platform, on which Amber’s closed-loop neuromodulation therapy for mixed urinary incontinence is being developedAmber Therapeutics has acquired Bioinduction Limited and its Picostim DyNeuMo platform, enhancing its capacity to develop closed-loop neuromodulation therapies for mixed urinary incontinence. This acquisition supports Amber's strategy to accelerate its first-in-human study (AURA-2) towards a pivotal trial in the US and ultimately commercialize their therapy on a global scale. The new integrated structure positions Amber as a unique entity in the UK for developing Class III Active implantable systems.